Jason Broderick | Authors


Apalutamide/Abiraterone Extends rPFS in Metastatic Castration-Resistant Prostate Cancer

February 11, 2021

In the phase 3 ACIS study, the addition of apalutamide to abiraterone acetate lead to a reduction in the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

Jelmyto Induces Durable Responses in Patients With Low-Grade Upper Tract UC

December 05, 2020

Treatment with mitomycin-containing reverse thermal gel, led to complete responses in over 50% of patients with low-grade upper tract urothelial carcinoma, which were maintained at 1 year, final results from the pivotal phase 3 OLYMPUS trial show.

Novel HIF-2α Inhibitor Achieved Durable Responses in VHL-Associated RCC

December 05, 2020

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

Nadofaragene Firadenovec Demonstrates Continued Efficacy Across Subgroups in BCG-Unresponsive NMIBC

December 03, 2020

In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.